Avacta Group Plc (AVCT) Given Corporate Rating at FinnCap
Avacta Group Plc (LON:AVCT)‘s stock had its “corporate” rating reissued by FinnCap in a research note issued on Monday. They presently have a GBX 200 ($2.60) target price on the biotechnology company’s stock. FinnCap’s target price would indicate a potential upside of 118.58% from the stock’s previous close.
Separately, Numis Securities Ltd reaffirmed a “buy” rating and set a GBX 160 ($2.08) price target on shares of Avacta Group Plc in a research report on Tuesday, April 4th.
Shares of Avacta Group Plc (LON:AVCT) traded up 5.17% during trading on Monday, reaching GBX 91.50. 26,742 shares of the company traded hands. The company’s market capitalization is GBX 62.57 million. The stock’s 50 day moving average is GBX 81.03 and its 200 day moving average is GBX 75.62. Avacta Group Plc has a 1-year low of GBX 60.00 and a 1-year high of GBX 110.00.
In other news, insider Michael Scott Albin purchased 5,731 shares of the business’s stock in a transaction on Thursday, April 6th. The shares were bought at an average price of GBX 62 ($0.81) per share, with a total value of £3,553.22 ($4,622.38).
Avacta Group Plc Company Profile
Avacta Group plc is a biotechnology company. Avacta’s focus is on its proprietary Affimer technology which is an engineered alternative to antibodies that has application in Life Sciences for diagnostics, therapeutics and general research and development. Affimer technology has been designed to address performance limitations of antibodies.
Receive News & Ratings for Avacta Group Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avacta Group Plc and related companies with MarketBeat.com's FREE daily email newsletter.